In this context, the identification of its biological targets in neurodegenerative diseases, such as Parkinson ́s and Alzheimer ́s, has allowed to understand its role in the onset and progression of these diseases at the molecular level, thus revealing AEP as a potential therapeutic target for the treatment of these conditions [9–14]. Here, LGMN is linked to neurodegenerative disease.